Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in MASH diagnosis and care.

A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to life-extending cardiac care for dogsIngelheim, Germany, and San Francisco, ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, ...

Ingelheim: Boehringer Ingelheim and Eko Health have entered a strategic collaboration agreement to improve heart murmur ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...

Biopharmaceutical company Boehringer Ingelheim is using data and more to drive organizational change and has outlined four ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next phase ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...